NRx Pharmaceuticals
Radnor, Florida, United States · Biopharma, Biotechnology, Health Care · 21 employees
This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. About NRx Pharmaceuticals, Inc. Clinical-stage biopharmaceutical company developing thera
Funding history
- Series seed — $3.5M — Mar 2025
- Funding Round — $11.0M — Nov 2022
Recent signals
- Apr 13, 2026: NRx Pharmaceuticals Appoints Glenn Tyson as Chief Commercial Officer
- Feb 17, 2026: SEC 8-K (8.01): On February 17, 2026, NRx Pharmaceuticals, Inc. issued a press release discussing its path to a new drug application for NRX-100 (ketamine), informed by real-world data and proposing a broader indication. This release follows a Type C meeting with the FDA, indicating significant progress in their drug development strategy. The information in the press release, attached as Exhibit 99.1, is crucial for stakeholders as it outlines potential advancements in treatment options.
- Jan 05, 2026: NRx Pharmaceuticals and neurocare Group AG establish partnership to create a nationwide network for neuroplastic therapy for depression and PTSD.
- Jun 16, 2025: NRx Pharmaceuticals and HOPE Therapeutics Form Strategic Investor Relations Partnership with astr partners.
- Mar 07, 2025: Raised $3.5M in Series seed
- Nov 18, 2024: NRx Pharmaceuticals Appoints Michael Abrams as Chief Financial Officer
- Nov 07, 2022: Raised $11.0M
See plans & pricing → Track NRx Pharmaceuticals’s funding, hiring, and signals — with verified contacts — on Fundz.